PTC Therapeutics’ STRIVE awards program seeks to provide monetary awards to patient advocacy organizations committed to developing unique and collaborative programs that will make meaningful contributions to the rare disease community by increasing awareness, diagnosis, education or fostering development of future patient advocates. The program is currently focused on the Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF) communities.
PTC Therapeutics respects and values the important services provided by the DMD and CF patient advocacy groups for individuals and families affected by these two rare disorders. In recognizing this, PTC encourages all DMD and CF patient advocacy groups, regardless of location, to submit proposals for novel and creative programs that will address any unmet need they see. Proposals to collaborate with other organizations to meet these needs are also welcome. These competitive one-year awards are established to support new programs that will benefit the DMD and CF communities through:
- Improving the diagnosis and treatment of patients
- Educating the general public and healthcare professionals
- Increasing the visibility of these devastating rare disorders
- Identifying and fostering the next generation of DMD patient advocates
For both the DMD and CF programs, one-year awards will be given to the most creative, feasible and sustainable proposals identified through a competitive submission process. Proposals will be reviewed by an external Review Committee who will not see identifying information contained in proposals except country of origin. The five members of the Review Committee were selected for their understanding of the rare disease community coupled with skills that include patient advocacy, philanthropy, communications, and knowledge of science.